What it is
Epitalon — also written epithalon — is a tetrapeptide: four amino acids, sequence AEDG (alanine, glutamic acid, aspartic acid, glycine).
Four is very short. BPC-157 has fifteen; thymosin beta-4 has forty-three. It was first identified in a pineal gland extract, and is based on a preparation called Epithalamin.
The claim
Epitalon is sold on an unusually direct proposition: that it activates telomerase and lengthens telomeres, and therefore slows ageing.
Most compounds in this library are sold on a proxy — better recovery, better sleep, better body composition. This one is sold on the thing itself, which makes it the outlier among the compounds marketed for longevity.
What has been published
The findings are real publications, not invention.
A 2003 paper reported that epithalon induced telomerase activity and telomere elongation in human somatic cells. Recent work reports that epitalon increases telomere length in human cell lines, through telomerase upregulation or alternative lengthening of telomeres — in both cancer and normal cells. Roughly 25 years of study exists, using cell, animal and computational methods.
The thing worth knowing about that literature
That body of work is dominated by one research group: Khavinson's, at the St Petersburg Institute of Bioregulation and Gerontology. The same programme produced Cartalax, whose file runs to six cell-culture papers, and Thymalin, whose runs to nearly three hundred — a spread worth knowing before treating the tradition as one body of evidence.
This is not an accusation. Originating groups often publish most of the early work on a compound, and that is how research starts. But a large literature produced largely by the people who originated the compound is a different kind of evidence from the same volume produced by unconnected laboratories, and readers weighing "25 years of research" deserve to know which kind they are looking at.
Recent review literature adds a second observation: despite the volume of biological and pharmacodynamic work, physico-chemical and structural investigation of the peptide remains quite limited. For a compound studied this long, that is a notable gap.
Whether the goal is even the right goal
There is an assumption inside the telomere claim that deserves examining.
Telomere shortening limits how many times a cell can divide. That limit is a constraint — and it is also part of how the body restrains cells that ought to stop dividing. Recent work on epitalon reports lengthening in cancer cells as well as normal ones.
A mechanism that removes a limit does not selectively remove it only where its removal would be welcome. Anyone treating telomere lengthening as self-evidently good is skipping the question that makes it interesting.
Where it stands
Approved as a medicine: nowhere.
FDA compounding status: appears among nominations withdrawn by the nominator, not on the current Category 2 list (page content current 2026-04-22).
Human evidence: no substantial independent human trial evidence was located.
Last checked
2026-09-07.